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Neuroparacoccidioidomycosis (neuroPCM) is the central nervous system infection by the fungus Paracoc-
cidioides brasiliensis. Its diagnosis is a difficult task that depends on neuroimaging techniques such as computed
tomography and magnetic resonance imaging. However, the detection of circulating P. brasiliensis antigens in
body fluids by inhibition enzyme-linked immunosorbent assay (inh-ELISA) has provided encouraging results.
In this study, 14 cerebrospinal fluid (CSF) and 11 serum samples of patients with neuroPCM were analyzed
by inh-ELISA for detection of circulating glycoprotein antigens of 43 kDa (gp43) and 70 kDa (gp70). Circu-
lating gp43 and gp70 antigens were detected in all CSF samples from patients with neuroPCM at mean
concentrations of 19.3 and 6.8 g/ml, respectively. In addition, both gp43 and gp70 antigens were detected in
10 of 11 serum samples analyzed at mean concentrations of 4.6 and 4.0 g/ml, respectively. By immunodiffusion
test, CSF samples were determined to be negative in 13 of 14 samples. The detection of anti-gp43 and anti-gp70
antibodies by conventional ELISA showed positive results for all CSF samples, with titers ranging from 1:50
to 1:51,200. Therefore, the high sensitivity of the inh-ELISA technique in detecting gp43 and gp70 antigens in
the CSF of neuroPCM patients strongly indicates that this assay can be considered as a powerful diagnostic
tool. In addition, the finding of anti-gp43 and anti-gp70 antibodies in CSF samples by conventional ELISA also
seems to be a promising diagnostic method for this special modality of PCM.
Paracoccidioidomycosis (PCM), a disease caused by Para-
coccidioides brasiliensis, particularly affects the poorer portions
of the population in Latin American countries, with a high
incidence in Brazil, where the disease is endemic. PCM pre-
dominantly affects 30- to 50-year-old adult males. It is uncom-
mon in childhood and relatively rare near puberty (3, 9). There
are a wide spectrum of clinical manifestations, ranging from
mild pulmonary lesions to severe disseminated forms involving
many organs, especially the mucosae, skin, lymph nodes, adre-
nals, and the central nervous system (CNS) (9). The primary
site of infection, which is often not apparent, is assumed to be
the lung. After being inhaled, P. brasiliensis causes a benign
and transient pulmonary infection that may be reactivated to
cause chronic disease (5, 11, 12). The involvement of the CNS
may occur more frequently than has been reported (21).
The involvement of the CNS in PCM, neuroparacoccidioid-
omycosis (neuroPCM), is secondary to the hematogenous dis-
semination of the fungus. NeuroPCM usually occurs as a man-
ifestation of widely disseminated disease but, occasionally,
CNS may be the sole location of the infection. Whenever the
CNS is involved, neuro-radiological methods such as computed
tomography (CT) and magnetic resonance imaging (MRI) are
needed for the identification of expansive lesions. NeuroPCM
is usually represented by multiple or solitary parenchymal le-
sions that lead to sensory or motor deficits, seizures, changes in
mental status, and intracranial hypertension (10, 22). However,
the definitive diagnosis of neuroPCM may only be obtained
after visualization of the fungus in biopsy material, fungal
isolation by culture, or by serological methods.
Considering the morbidity associated with the invasive neu-
rologic procedures, clinicians are not prone to recommend
aspiration or biopsy of CNS lesions. Therefore, sensitive and
specific immunodiagnostic assays to determine the presence of
P. brasiliensis in cerebrospinal fluid (CSF) specimens are in-
dispensable. Recently, Marques da Silva et al. (15–17) de-
scribed an antigen detection assay (the inhibition enzyme-
linked immunosorbent assay [inh-ELISA]) for the gp43 and
gp70 molecules of P. brasiliensis that has a good potential for
the diagnosis and follow up of patients with PCM. The detec-
tion of P. brasiliensis antigens in body fluids might facilitate the
early diagnosis of PCM, including patients with cerebral le-
sions.
In the present study, gp43 and gp70 antigens of P. brasiliensis
were detected in CSF and serum samples from patients with
neuroPCM by using an inh-ELISA, and the results were com-
pared to those obtained for anti-P. brasiliensis antibodies de-
tected by immunodiffusion (ID) and conventional ELISA tests.
MATERIALS AND METHODS
Patients and samples. CSF and serum samples were obtained from 14 patients
with neuroPCM whose selection was based on the clinical, serological and to-
mographic findings. The patients enrolled in the present study were taken from
Hospital São Paulo, São Paulo Federal University, and Hospital das Clı́nicas da
Universidade Estadual de Campinas, Campinas, São Paulo, Brazil. All patients
were male with a mean age of 45 years. The diagnosis of systemic PCM was
established in all of the patients based on the visualization and/or culture of the
fungus in clinical specimens. The neurological involvement was ascertained
based on clinical and tomographic findings, as well as on the clinical response to
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antifungal treatment. All patients had simultaneous involvement of other organs
from which clinical specimens confirmed the diagnosis of PCM. A lumbar punc-
ture was performed in all cases as part of the routine medical assistance at those
institutions. In addition, serum samples from 11 patients were also requested to
investigate the etiology of the neuroinfection. Control groups included 10 CSF
samples from patients with noninfectious neurologic diseases and 30 serum
samples from healthy volunteers (blood donors). The study was evaluated and
approved by the Ethics Committee of our institution.
Fungal isolates, antigen preparations, and gp70/gp43 purifications. P. brasil-
iensis B-339 (ATCC 200273) and Pb 113 were obtained from the culture collec-
tion of the Disciplina de Biologia Celular, Universidade Federal de São Paulo.
The isolates were transformed to the yeast phase, and exoantigen was produced
according to the method of Camargo et al. (7, 8). Gp43 was purified from the Pb
B-339 crude exoantigen as described elsewhere (23), and gp70 was purified from
Pb 113 cytoplasmic antigen as described previously (17). Protein content was
determined by the Bradford method (4).
MAb production. Monoclonal antibody (MAb) anti-gp43 was a gift from R.
Puccia (23), and MAb anti-gp70 was prepared as described by Mattos Grosso et
al. (18).
Pretreatment of CSF and sera for inh-ELISA. Aliquots of CSF and serum (200
l) were mixed with an equal volume of 0.1 M EDTA (Sigma; pH 7.2) and boiled
at 100°C for 5 min. After cooling, tubes were centrifuged at 13,000  g for 30
min, and the supernatants were used for the test.
Detection of circulating gp43 and gp70 antigens by inh-ELISA. inh-ELISA
was performed as previously described (13, 15). First, a standard inhibition curve
was prepared by adding known concentrations of gp43 or gp70 to a pool of
normal human serum or CSF controls in different plates (inhibition standards)
(13, 15). The inhibition reaction occurred when constant aliquots of MAbs
anti-gp43 or anti-gp70 were mixed with the inhibition standards, PCM patient
sera, or CSF samples and normal human serum and CSF control samples.
Samples were then plated on previously blocked microtiter plate (inhibition
plate) and incubated overnight at 4°C. Reaction plate was coated with gp43 or
gp70 and incubated overnight at 4°C. Free sites on plastic were blocked with 5%
skim milk in phosphate-buffered saline (PBS)–Tween 20, and samples from each
well in the inhibition plate (containing a mixture of MAb [anti-gp43 or anti-gp70]
bound to circulating antigen and free MAb) were transferred to the respective
wells in the reaction plate. The plate was washed, probed with goat anti-mouse
immunoglobulin G-peroxidase conjugate, and developed with a chromogenic
substrate as previously described (13, 15). Optical density (OD) readings at 492
nm were then plotted on a standard curve constructed from the data derived
from MAb titration with the inhibition standards. The antigen concentrations in
the patient’s CSF and serum samples were calculated with a regression model
constructed with the reciprocal values of fixed concentrations of gp43 or gp70
and the OD values. All tests were made in duplicates. The cutoff point was
established by the receiver operator characteristic (ROC) curve.
ID test. ID tests were performed with CSF and serum samples at the moment
of diagnosis of neuroPCM as previously described (7).
ELISA. Microtiter plates (Costar) were coated with 100 l of purified gp43 or
gp70 (500 ng/well), diluted in 0.06 M carbonate-bicarbonate buffer (pH 9.6), and
incubated overnight at 4°C. The plates were washed three times with PBS-Tween
20 (0.05%) and free sites were blocked with 5% skim milk in PBS-Tween 20 (200
l/well) for 2 h at 37°C. After three washes, 100 l of CSF samples (1:50 to
1:51,200 dilution) of each patient was added to each well, and the plates were
incubated at 37°C for 1 h. Plates were then washed again; 100 l of peroxidase-
labeled goat anti-human immunoglobulin G (1:1,000; Sigma) was added to each
well, and the plates were incubated for 1 h at 37°C. After three washes, the
reaction was developed by the addition 100 l of a mixture of o-phenylenedi-
amine (0.2 mg/ml; Sigma) and 0.05% (vol/vol) H2O2. After 5 min of incubation
in the dark, the reaction was stopped with 50 l of 4 N H2SO2. The OD was
measured at 492 nm by using an ELISA Microplate reader (Titertek Multiskan
MCC/340).
Statistical analysis. Inhibition standard curves were performed in duplicates
for at least four independent assays. The data were statistically analyzed by the
Stata 7.0 version for Windows 98/95/NT (Stata Corp., College Station, TX), and
the specificity and sensitivity were determined by using the ROC.
RESULTS
Detection of P. brasiliensis gp43 and gp70 antigens in CSF by
inh-ELISA. A standard inhibition curve was prepared, and the
cutoff values of 0.23 g/ml for gp43 and 0.21 g/ml for gp70
were determined by using the ROC curve. CSF samples with
concentrations above these values were considered as positive.
gp43 and gp70 were detected in all 14 CSF samples (100%).
The mean antigen concentration for gp43 (19.3 g/ml) was
found to be significantly higher than that for gp70 (6.8 g/ml [P
TABLE 1. Serological results of 14 patients with neuroPCM and control groups evaluated by inh-ELISA, ID, and ELISA
Subject
CSF antigen concn
(g/ml)a CSF titer (ELISA)
b Serum antigen
concn (g/ml)a Antibody titer (ID)
gp43 gp70 Anti-gp43 Anti-gp70 gp43 gp70 CSF Serum
Case 1 19.5 6.75  (1:1,600)  (1:1,600) NAd NA NRc NA
Case 2 24.0 6.75  (1:400)  (1:50) NA NA NR NA
Case 3 0.46 0.43  (1:200)  (1:50) NA NA NR NA
Case 4 3.75 1.83  (1:50)  (1:50) 2.85 1.03 NR NR
Case 5 21.0 6.75  (1:6,400)  (1:400) 5.27 1.49 NR 1:8
Case 6 18.0 4.16  (1:200)  (1:50) 5.27 2.49 NR 1:4
Case 7 22.5 3.39  (1:50)  (1:50) 0 1.03 NR NA
Case 8 13.5 2.67  (1:50)  (1:50) 1.21 0 NR NA
Case 9 16.5 8.25  (1:50)  (1:50) 4.16 1.77 NR NDSe
Case 10 19.5 7.5  (1:200)  (1:50) 1.03 11.25 NR NDS
Case 11 30.0 16.5  (1:200)  (1:50) 4.16 1.68 NR NR
Case 12 30.0 13.5  (1:50)  (1:50) 7.12 2.49 NR NR
Case 13 25.5 5.64  (1:50)  (1:50) 12.75 8.25 NR NR
Case 14 25.5 6.38  (1:51,200)  (1:50) 6.75 11.25 1:16 1:16
Mean 19.3 6.8 4.6 4.0
Control group Ag 0 0 ()f ()
Control group Bh 0 0 NR NR
a Antigen detection by inh-ELISA.
b Antibody detection by conventional ELISA.
c NR, nonreactive.
d NA, not available.
e NDS, positive with nondiluted sera.
f (), negative.
g Ten CSF samples from noninfectious neurologic diseases were negative for antigens and antibodies (control patients).
h Thirty serum samples from healthy volunteers were negative for antigens and antibodies (control patients).
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 0.001]). CSF samples from individuals with diseases other
than PCM had undetectable antigen levels (Table 1).
Detection of gp43 and gp70 antigens in sera samples by
inh-ELISA. A standard inhibition curve was prepared, and the
cutoff values of 0.23 g/ml for gp43 and 0.97 g/ml for gp70
were determined by using the ROC curve. Samples with con-
centrations greater than these values were considered positive.
gp43 and gp70 antigens were detected in 10 of 11 patient sera.
Despite some differences in the mean concentrations of gp43
and gp70 in serum samples, they were not statistically signifi-
cant (P  0.65). The mean concentration of gp43 was always
higher than gp70 in CSF and serum samples.
Detection of antibodies by ID and ELISA. Only 1 CSF sam-
ple (7.2%) of 14 was positive by ID using P. brasiliensis crude
exoantigen, at an 1:16 titer (7.2%). Five of eleven (45.5%) sera
were found to be positive by ID, with antibody titers ranging
from 1:4 to 1:16; for two of those sera, however, positive
reactions were obtained only with undiluted samples. On the
other hand, 14 of 14 CSF samples (100%) had anti-gp43 and
anti-gp70 antibodies, with titers ranging from 1:50 to 1:51,200
by ELISA (Table 1).
DISCUSSION
Diagnosis of neuroPCM is a difficult task and depends on
imaging techniques besides mycologic and serological findings.
The reported frequency of CNS involvement in PCM is ex-
tremely variable depending on the approach that defines the
cases. In necropsy studies, neuroPCM has been found in 9.65
to 27.18% of the PCM cases. Most of the neuroPCM patients
present simultaneous involvement of other organs, but isolated
CNS involvement may also occur (21). The accurate diagnosis
of neuroPCM is obtained by the detection or isolation of the
fungus in samples taken from cerebral lesions or in CSF (1, 2,
21, 22). Usually, classical CSF mycologic examinations (mi-
croscopy and culture) generate negative results, and tissue
samples are requested to check for the presence of fungal
components. A recent report by Pereyra (22) evaluated the
clinical, radiologic, and laboratory findings of 13 cases of neu-
roPCM in which the authors detected gp43 in tissue samples of
all patients by immunofluorescence (22). However, considering
the morbidity related to invasive procedures necessary to ob-
tain a brain biopsy, an accurate serological tool based on spe-
cific detection of antigen or antibodies against the fungus is
clearly necessary to improve the diagnosis of neuroPCM. In
this regard, Almeida et al. detected specific anti-gp43 antibody
in eight of nine samples of CSF obtained from patients with
neuroPCM (1).
Usually, ID is the method of choice for antibody detection in
PCM sera, with a positivity reaching 97.1% by using a 7-day
crude exoantigen preparation, in which gp43 is the predomi-
nant molecule, representing 80 to 85% of the total antigenic
composition (7). An antigen preparation containing large
amounts of gp43 is essential for a definitive diagnosis by ID,
and its sensitivity can be compared to purified gp43 prepara-
tions. Serologic negative results may be observed even when
cells of P. brasiliensis are found in biological materials; in these
cases, they may be related to low-avidity immunoglobulin G2
antibodies directed against carbohydrate epitopes (20). ELISA
tests may help in the diagnosis of neuroPCM; however, prob-
ably due to the high sensitivity of the method, cross-reactions
may occur, mainly with histoplasmosis sera (19). On the other
hand, ELISA is very useful for monitoring PCM patients under
antimycotic therapy. The detection of circulating P. brasiliensis
antigens (gp43 and gp70) in body fluids by inh-ELISA has
recently shown promising results in patients with PCM (13–
17).
In the present study, circulating gp43 and gp70 were de-
tected in all CSF samples from patients with neuroPCM, with
mean antigen concentrations of 19.3 and 6.8 g/ml, respec-
tively. gp43 and gp70 were also detected in 10 (91%) serum
samples of 11 samples obtained from 14 patients, with mean
antigen concentrations of 4.6 and 4.0 g/ml, respectively.
Moreover, the antigen concentrations were found considerably
higher in CSF than in sera, suggesting their local production,
and the concentration of gp43 was always higher in relation to
gp70.
Our results are in agreement with those of Almeida et al.
(1), who found only one patient (7.1%) to be positive for
anti-P. brasiliensis antibodies in CSF by ID test in their study.
ELISA, a more sensitive test, detected anti-gp43 and anti-gp70
antibodies in all (100%) CSF samples, confirming that ELISA
is a better test for that purpose. Thus, search for anti-gp43 and
anti-gp70 antibodies in CSF samples by ELISA seems prom-
ising as a diagnostic method for neuroPCM.
Our results suggest that monitoring specific antigens of P.
brasiliensis may be helpful to define the diagnosis of neu-
roPCM. It was found that both gp43 and gp70 were detectable
in almost all of the serum samples, with small differences in
their mean antigen concentrations (4.6 and 4.0 g/ml, respec-
tively). Of note, the CSF gp43 antigen concentrations were
substantially higher than the gp70 concentrations (19.3 versus
6.8 [P  0.001]). On the other hand, antibody detection was
negative when tested by ID but was positive against both an-
tigens when tested by ELISA, despite being at low titers. These
data, from the limited number of patients studied, allow us to
assume that the detection of antigen by inh-ELISA or the
detection of specific antibody by conventional ELISA may be
equally sensitive for identifying neuroPCM. Since antigen val-
ues for gp43 were always higher than those found for gp70,
assaying only for gp43 may prove sufficient for that purpose.
Detection of antibody by conventional ELISA, as a routine
laboratory work, is a less cumbersome and time-consuming
procedure than the detection of antigen. Hence, testing CSF
samples for antigens would be recommended only when a
suspected patient presents either negative or inconsistent re-
sults for antibody detection.
In light of the scarce clinical and radiological information
available about the enrolled patients, no correlation could be
ascertained between antigen levels and severity of the disease.
Also, further studies are necessary to validate the potential
usefulness of antigen detection for monitoring the patients’
response to antifungal therapy.
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